Enimmune corporation

Enimmune corporation

TTPEX:6564
15.10
TWD
+0.10
(+0.67%)
1.15BMarket Cap

Total Valuation

TWD

As of June 30, 2026, Enimmune corporation carries a market capitalization of 1.15B, placing it among publicly traded companies globally. Its enterprise value stands at 1.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.15B
Enterprise Value1.12B

Share Statistics

As of June 30, 2026, Enimmune corporation has 72.13M shares outstanding.

Shares Outstanding72.13M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio11.48
P/TBV Ratio303.08

Financial Position

As of June 30, 2026, Enimmune corporation maintains a current ratio of 1.01, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

Current Ratio1.01
Quick Ratio0.73
Debt / Equity158.95

Financial Efficiency

These figures cover the twelve months ended June 30, 2026.

Employee Count35.00

Stock Price Statistics

TWD

As of the close on November 17, 2026, Enimmune corporation's stock has declined approximately 26.76% over the past 52 weeks. The 50-day moving average sits at 15.73, while the 200-day moving average is 17.26.

52-Week Price Change-26.76%
50-Day Moving Average15.73
200-Day Moving Average17.26

Balance Sheet

TWD

As of June 30, 2026, Enimmune corporation holds 193.45M in cash and equivalents against 159.57M in total debt, resulting in a net debt position of -14.28M. Total book value stands at 100.39M, with working capital of 3.74M providing operational flexibility.

Cash & Cash Equivalents193.45M
Total Debt159.57M
Net Debt-14.28M
Equity (Book Value)100.39M
Book Value Per Share1.39
Working Capital3.74M

Stock Splits

Enimmune corporation's most recent stock split took place on October 28, 2026.

Last Split Date10/28/2026